Iris Conaids Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 10-12-2024
- Paid Up Capital ₹ 0.10 M
as on 10-12-2024
- Company Age 12 Year, 9 Months
- Last Filing with ROC 31 Mar 2024
- Revenue -21.53%
(FY 2022)
- Profit -53.22%
(FY 2022)
- Ebitda 44.66%
(FY 2022)
- Net Worth 5.37%
(FY 2022)
- Total Assets 22.00%
(FY 2022)
About Iris Conaids
The Company is engaged in the Machinery And Equipment Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Zainul Bandukwala, Naseman Bandookwala, and Aftab Bandukwala serve as directors at the Company.
- CIN/LLPIN
U52300GJ2012PTC069759
- Company No.
069759
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
09 Apr 2012
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Ahmedabad, Gujarat, India
- Telephone
- Email Address
- Website
-
- Social Media-
What products or services does Iris Conaids Private Limited offer?
Iris Conaids Private Limited offers a wide range of products and services, including Disinfectant Chemicals, Antimicrobial Chemical, Spray Painting Equipment, Airless Painting Machine, Surface Coating & Paint Equipment, Paint Applicators, Rust & Corrosion Protection Products, Anti Corrosion Coating, Putty Knife, Building & Construction Machines.
Who are the key members and board of directors at Iris Conaids?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Zainul Bandukwala  | Director | 17-Sep-2020 | Current |
| Naseman Bandookwala | Director | 07-Feb-2024 | Current |
| Aftab Bandukwala | Director | 09-Apr-2012 | Current |
Financial Performance of Iris Conaids.
Iris Conaids Private Limited, for the financial year ended 2022, experienced significant reduction in revenue, with a 21.53% decrease. The company also saw a substantial fall in profitability, with a 53.22% decrease in profit. The company's net worth moved up by a moderate rise of 5.37%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Iris Conaids?
In 2023, Iris Conaids had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Iris Conaids?
Unlock and access historical data on people associated with Iris Conaids, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Iris Conaids, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Iris Conaids's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
